# A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct01951235` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01951235](<https://clinicaltrials.gov/study/NCT01951235>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01951235

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 315 participants.

## Technical summary

Registry record NCT01951235. Randomized; quadruple masking; primary purpose treatment. Start 2013-01 (registry gives no type); primary completion 2014-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 315 participants (enrolled count; ClinicalTrials.gov record NCT01951235, source copy `cardio:ctgov-nct01951235-2015-08-13`, retrieved 2026-10-26)
- Start date: 2013-01 (registry gives no type) (ClinicalTrials.gov record NCT01951235, source copy `cardio:ctgov-nct01951235-2015-08-13`, retrieved 2026-10-26)
- Primary completion: 2014-07 (actual) (ClinicalTrials.gov record NCT01951235, source copy `cardio:ctgov-nct01951235-2015-08-13`, retrieved 2026-10-26)
- Completion: 2014-07 (actual) (ClinicalTrials.gov record NCT01951235, source copy `cardio:ctgov-nct01951235-2015-08-13`, retrieved 2026-10-26)
- Countries: Latvia (ClinicalTrials.gov record NCT01951235, source copy `cardio:ctgov-nct01951235-2015-08-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01951235-2015-08-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Imeglimin
- Intervention (Drug): Placebo
- Lead sponsor: Poxel SA
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: ab10ac2fcc1cf4ff9e97f7ccac59868d2acc0be404ae0a8721f03038323045ff
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
